Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

SDP enters MOU worth potential $3bn for option to buy up to 11 Roivant vants; later signs definitive agreement, then completes M&A

Executive Summary

Through a non-binding memorandum of understanding (MOU), Sumitomo Dainippon Pharma Co. Ltd. (SDP) and Roivant Sciences Inc. plan to forge an alliance involving the clinical-stage assets of multiple Roivant biopharmaceutical divisions (known as vants). The potential partners will conduct due diligence and expect to sign a definitive agreement by the end of October 2019.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Includes M&A Option

Related Companies